Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension

• Main Authors: Wenxing Dong (Author), Zhe Zhang (Author), Mingming Chu (Author), Peng Gu (Author), Min Hu (Author), Lulu Liu (Author), Jingbin Huang (Author), Rong Zhang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Adding selexipag to the combined treatment of endothelin receptor antagonists (ERA) and phosphodiesterase 5 inhibitor (PDE5i) reduces the risk of clinical worsening events in patients with pulmonary arterial hypertension (PAH) but at a considerably higher cost. This study evaluated the co...